Novozymes Biopharma will present a new scientific poster on recombinant human albumin at the 2011 AAPS National Biotechnology Conference on 16-18 May in San Francisco, California.
The poster reveals the results of the company's latest study on the use of recombinant human albumin for the stabilisation of therapeutic proteins.
The therapeutic and, ultimately, commercial success of a protein-based drug depends upon the ability to produce a formulation with an adequate stability profile.
The mechanisms of protein instability are complex and, typically, multiple excipients are required to address factors such as aggregation, oxidation and nonspecific adsorption during protein formulation.
The new poster, entitled 'Recombinant human albumin: a multifunctional excipient for the stabilisation of therapeutic protein formulations', demonstrates the potential for recombinant human albumin (rAlbumin) to act as a multifunctional stabilisation excipient for protein and peptide formulations.
The poster describes the study undertaken to investigate the stability of the rAlbumin with respect to pH and temperature to assess the suitability of this molecule for incorporation into protein formulations.
The study results indicate that rAlbumin is a multifunctional excipient, protecting protein-based active ingredients against aggregation, oxidation and non-specific binding in solution.
The multifunctional nature of rAlbumin may lead to opportunities to explore simpler protein formulations with reduced numbers of excipients.
Additionally, the stability of the molecule reveals its potential to be used under a range of formulation conditions.
